<DOC>
	<DOCNO>NCT02028442</DOCNO>
	<brief_summary>This multicentre , open-label , Phase I/II study enadenotucirev patient either solid tumour epithelial origin respond standard therapy standard treatment exists ( Phase I dose escalation stage Single cycle ) , mCRC respond standard therapy ( Phase I dose escalation Repeat cycle cohort expansion stage ) , mCRC respond standard therapy advance metastatic bladder cancer candidate chemotherapy ( Phase Ib ) mCRC stable disease partial response 3-4 month first line standard care chemotherapy ( Phase II ) .</brief_summary>
	<brief_title>Phase I / II Study Enadenotucirev Sub-acute Fractionated IV Dosing Cancer Patients</brief_title>
	<detailed_description />
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Urinary Bladder Neoplasms</mesh_term>
	<criteria>Patients must provide write informed consent Age ≥ 18 year patient must least legal age limit able give consent within jurisdiction study take place . ECOG performance status 0 1 Predicted life expectancy 3 month Ability comply study procedure Investigator 's opinion Recovered Grade 1 effect ( exclude alopecia ) prior therapy malignancy Adequate renal function Creatinine ≤ 1.5 mg/dL calculate creatinine clearance use CockcroftGault formula ≥ 60 mL/min , measure creatinine clearance ≥ 60 mL/min , Haematuria : dipstick ≤ 2+ Proteinuria : dipstick ≤ 2+ Adequate hepatic function Serum bilirubin &lt; 1.5 mg/dL Aspartate transaminase ( AST ) alanine transaminase ( ALT ) ≤ 3x upper limit normal ( ULN ) Adequate bone marrow function : Absolute neutrophil count ( ANC ) ≥ 1.5 x 109/L Platelets ≥ 100 x 109/L Haemoglobin ≥ 100 g/L UCC ≥ 90 g/L cancer Adequate coagulation test : international normalised ratio ( INR ) ≤ 1.5 x ULN For female childbearing potential ( define &lt; 2 year last menstruation surgically sterile ) , negative serum pregnancy test must document within 14 day prior first administration study treatment For woman postmenopausal ( 24 month amenorrhea ) surgically sterile ( absence ovary and/or uterus ) : agreement use two adequate method contraception , treatment period least 3 month last dose study drug For men : agreement use barrier method contraception treatment period least 6 month last dose study drug At least 3 week since dose IV systemic chemotherapy least two week since oral dose capecitabine time first administration ColoAd1 . Phase I Specific Dose Escalation Stage ( except Repeat Cycle Cohort ) : Solid tumour epithelial origin respond standard therapy standard treatment exist Dose Expansion Stage Single Cycle Dose Escalation Stage Repeat Cycle Cohort : mCRC respond standard therapy ≤ 3 prior line systemic therapy advance disease OR ≤ 4 prior line systemic therapy advance disease one 4 line anti EGFR therapy give single agent combine previously administer chemotherapy regimen Phase Ib : mCRC respond standard therapy 3 prior line systemic therapy advance disease OR 4 prior line systemic therapy advance disease one 4 line anti EGFR therapy give single agent combine previously administer chemotherapy regimen Advanced metastatic UCC , receive maximum one chemotherapycontaining regimen maximum one systemic treatment biologic agent . Phase II Specific mCRC Have receive 3 4 month first line chemotherapy either FOLFOX , FOLFIRI CAPOX , without bevacizumab At least one measurable lesion accord RECIST 1.1 criterion Documented partial response stable disease Eligible receive chemotherapy FOLFOX CAPOX short chemotherapy interruption ( 3 4 week ) Exclusion Criteria Patients : Pregnant breast feeding female ; Known history evidence significant immunodeficiency due underlie illness ( e.g . human immunodeficiency virus [ HIV ] /acquired immunodeficiency syndrome [ AIDS ] ) and/or medication ( e.g . systemic corticosteroid , immunosuppressive medication include cyclosporine , azathioprine , interferon , within past 4 week ) Splenectomy Prior allogeneic autologous bone marrow organ transplantation Active infection require antibiotic , physician monitoring , recurrent fever &gt; 38.0 degree centigrade associate clinical diagnosis active infection Active viral disease know positive serology HIV , hepatitis B hepatitis C ; Use follow antiviral agent : ribavirin , adefovir , lamivudine cidofovir within 7 day prior day 1 ; pegylated interferon ( PEGIFN ) ( within 14 day prior first administration ColoAd1 ) Administration investigational drug within 28 day prior first dose ColoAd1 Major surgery within 4 week radiotherapy within 3 week prior first dose ColoAd1 Another primary malignancy within past 3 year ( except non melanoma skin cancer cervical cancer situ ) Central nervous system ( CNS ) metastasis symptomatic and/or require treatment Any condition illness , opinion Investigator medical monitor , would compromise patient safety interfere evaluation safety drug Known allergy treatment medication excipients Any medical psychological condition would preclude participation study compromise ability give inform consent Phase II Specific Progression first line therapy A complete response first line therapy Use first line therapy longer 4 month Use first line treatment chemotherapy regimen FOLFOX , FOLFIRI CAPOX ( without bevacizumab ) More 6 week since last administration 5 FU , capecitabine , oxaliplatin irinotecan</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>